BlueBird Bio's 2-day reckoning is at hand - News - MM+M
Bluebird Bio has 'doubts' about continuing to do business through 2022, announces CFO resignation | Fierce Pharma
bluebird bio submits BLA for single-dose gene therapy to treat beta-thalassemia
bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies - Pharmaceutical Technology
Bluebird Bio Reports No Evidence that LentiGlobin for Sickle Cell Causes AML
Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license - Boston Business Journal
PharmaShots Interview: bluebird bio's Rich Colvin Shares Insights on the Skysona to Treat Early Cerebral Adrenoleukodystrophy
Bluebirdbio Announces The Lifting Of FDA Clinical Hold for Sickle Cell Disease And β-Thalassaemia Studies – TIF
Low on cash, Bluebird Bio and its gene therapies face uncertain future
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies | Business Wire
Bluebird Bio CEO on new study data: We're getting profound responses
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions | Business
Nick Leschly, CEO of bluebird bio spinout 2seventy bio says 2023 will be a 'special year' - Boston Business Journal
Bluebird Bio CEO defends $1.8 million price tag for new gene therapy
bluebird bio (@bluebirdbio) / Twitter
Bluebird Bio Eliminating 30% of Workforce in Restructuring
Bluebird Bio's Rare Disease Gene Therapies Recommended for FDA Approval
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics? | The Motley Fool
Bluebird's Gene Therapy; Neurocrine-Sosei's Pact; Twist-Abveris's Deal
Bluebird Bio Launches First Gene Therapy for Beta Thalassemia in Germany
Cambridge gene therapy firm bluebird bio to move to Somerville - Boston Business Journal
Bluebird Bio gene therapy wins first FDA approval for rare blood disorder - MedCity News
ICER says bluebird bio's $2.1m gene therapy is cost-effective | pharmaphorum
Bluebirdbio hi-res stock photography and images - Alamy
Articles with bluebird bio
JPMorgan Day 3: Bluebird Bio preps for beti-cel launch
Why Bluebird Bio (BLUE) Stock Is Getting Hammered | Markets Insider
